Study: For complex cases of NMOSD, Ultomiris found safe, effective
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
The gut hormone GLP-1 may drive brain inflammation in NMOSD patients, leading to nausea, vomiting, or hiccups, called area postrema syndrome.| Neuromyelitis News
Bilateral vision loss, the use of a walking aid, fatigue, and depression predict employment loss after a NMOSD diagnosis, a study shows.| Neuromyelitis News
Ultomiris, an approved infusion therapy for neuromyelitis optica spectrum disorder, is closer to being eligible for reimbursement in Canada.| Neuromyelitis News
Over a recent concert weekend, columnist Jennifer V. and a U.S. friend bonded over the similarities between their cases of NMOSD and MOGAD.| Neuromyelitis News
A study linked late-onset neuromyelitis optica spectrum disorder to worse recovery from relapses and faster disability progression.| Neuromyelitis News
Since her NMOSD diagnosis, columnist Jennifer V. has found routines crucial for distinguishing between bad days and signs of a flare-up.| Neuromyelitis News
For columnist Jennifer V., telehealth appointments have made care more accessible, but some things just can't be done virtually, she says.| Neuromyelitis News
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
The platelet-to-lymphocyte ratio may be used as a biomarker of disability severity in people with NMOSD, a study found.| Neuromyelitis News
Columnist Jennifer V. explains what "bed rotting" is and how it can be useful for NMOSD patients who need rest and recovery to avoid flares.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Living with NMOSD and its resulting disability can make it hard to find and keep employment, a new U.S. study highlights.| Neuromyelitis News
Depression, anxiety, and sleep disturbances are common among patients with neuromyelitis optica spectrum disorder, a new meta-analysis shows.| Neuromyelitis News
Columnist Candice Galvan shares how she came to realize that to better care for her daughter, she needed to protect her own mental health.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
NMOSD may begin to manifest as hard-to-treat nausea, vomiting, or hiccups — a condition called area postrema syndrome — delaying a diagnosis.| Neuromyelitis News
NMOSD patients who have had only one relapse tend to underestimate their future relapse risk, but this pattern changes with more relapses, a study finds.| Neuromyelitis News
Taking ginseng tablets twice a day for three months lessened fatigue in people with NMOSD, a placebo-controlled Phase 3 trial found.| Neuromyelitis News
What others may see as mood swings, columnist Jennifer van Amerom argues, are often reactions to trauma or treatment.| Neuromyelitis News
Neuromyelitis optica spectrum disorder patients whose first symptoms affect the brainstem are often misdiagnosed and have more relapses, a study finds.| Neuromyelitis News
With optic neuritis symptoms lingering despite treatment, columnist Jennifer van Amerom is trying to listen to what her body tells her.| Neuromyelitis News
After a series of plasma exchange sessions, columnist Jennifer van Amerom is hoping her vision fully returns to normal.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
Career changes, new home hunts, and symptom flares are a lot to handle, says columnist Jennifer van Amerom, who's juggling life and NMOSD.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News
Uplizna safely provided sustained disease control for NMOSD patients, according to final data from a Phase 2/3 clinical trial.| Neuromyelitis News
